302 related articles for article (PubMed ID: 18584104)
1. [Harmonisation of the Marketing Authorisation Application dossier: perspectives due to harmonised requirements. Assessing Rules and the Common Technical Document].
Menges K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):748-56. PubMed ID: 18584104
[TBL] [Abstract][Full Text] [Related]
2. [Marketing of medicinal products in the European Community. The Mutual Recognition and Decentralised Procedures].
Bachmann P
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):722-30. PubMed ID: 18560780
[TBL] [Abstract][Full Text] [Related]
3. [The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure].
Enzmann H; Schneider C
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):731-9. PubMed ID: 18584106
[TBL] [Abstract][Full Text] [Related]
4. [EU law on marketing authorization of medicines. History, current state of development and perspectives].
Nettesheim M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):705-12. PubMed ID: 18560781
[TBL] [Abstract][Full Text] [Related]
5. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
[TBL] [Abstract][Full Text] [Related]
6. [Marketing authorization for pharmaceuticals: the necessity of European collaboration].
Seitz R; Enzmann H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):703-4. PubMed ID: 18592336
[No Abstract] [Full Text] [Related]
7. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
Lehmann B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
[TBL] [Abstract][Full Text] [Related]
8. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
9. [The regulatory framework for complementary and alternative medicines in Europe].
Knöss W; Stolte F; Reh K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
[TBL] [Abstract][Full Text] [Related]
10. [Revision of the Renewals Procedure and the implementation of the sunset clause. BfArM's experience with the amended legislation].
Horn M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):740-7. PubMed ID: 18584105
[TBL] [Abstract][Full Text] [Related]
11. [Master files: less paper, more substance. Special rules for special medicines: Plasma Master File and Vaccine Antigen Master File].
Seitz R; Haase M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):764-70. PubMed ID: 18560779
[TBL] [Abstract][Full Text] [Related]
12. [The network of official medicines control laboratories].
Buchheit KH; Wanko R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1139-44. PubMed ID: 25192832
[TBL] [Abstract][Full Text] [Related]
13. Internationalization of regulatory requirements.
Juillet Y
Fundam Clin Pharmacol; 2003 Feb; 17(1):21-5. PubMed ID: 12588627
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.
Regnstrom J; Koenig F; Aronsson B; Reimer T; Svendsen K; Tsigkos S; Flamion B; Eichler HG; Vamvakas S
Eur J Clin Pharmacol; 2010 Jan; 66(1):39-48. PubMed ID: 19936724
[TBL] [Abstract][Full Text] [Related]
15. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
16. Changing standards for drug approval: A longitudinal analysis of conditional marketing authorisation in the European Union.
Hoekman J; Boon W
Soc Sci Med; 2019 Feb; 222():76-83. PubMed ID: 30605802
[TBL] [Abstract][Full Text] [Related]
17. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
Enzmann H; Broich K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
[TBL] [Abstract][Full Text] [Related]
18. Drug safety in the European community.
Sauer F
Drug Saf; 1990; 5 Suppl 1():141-8. PubMed ID: 2182057
[TBL] [Abstract][Full Text] [Related]
19. International Conference on Harmonisation; guidance on M4 common technical document; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 Oct; 66(200):52634-7. PubMed ID: 12358037
[TBL] [Abstract][Full Text] [Related]
20. ICH: an exclusive club of drug regulatory agencies and drug companies imposing its rules on the rest of the world.
Prescrire Int; 2010 Aug; 19(108):183-6. PubMed ID: 20939460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
